Research guide / AHK-Cu

What is AHK-Cu? A Complete Research Guide.

Updated August 2026 · 9 minute read

AHK-Cu is a copper-binding tripeptide studied mainly in hair biology. This guide separates the published follicle and cell research from what regulators have actually said — and is explicit about how thin the human evidence is.

Research information only. This article summarises published research. It is not medical advice, a dosing guide, or a recommendation to use any product. Laboratory and ex vivo findings do not predict an individual outcome, and AHK-Cu is not an approved medicine.

01 / Overview

What is AHK-Cu?

AHK-Cu is the copper complex of AHK (L-alanyl-L-histidyl-L-lysine), a synthetic tripeptide analogous to the naturally occurring GHK. Like GHK-Cu, it binds copper(II) ions with high affinity; its research focus has been hair biology rather than skin.[1]

Copper tripeptides as a class are described in the review literature as growth-factor-like signals for differentiated cells — stimulating fibroblast proliferation, raising vascular endothelial growth factor (VEGF), and lowering transforming growth factor-beta1 (TGF-β1) secretion in cell systems. These class-level observations frame why researchers tested AHK-Cu on hair follicles.[3]

The critical fact about AHK-Cu is what is missing: there are no human clinical trials — no randomised studies, no registered development programme, no approved product anywhere. Every published finding comes from ex vivo hair follicles or cultured cells. That absence shapes everything below.

View the AHK-Cu research listing

02 / Mechanism

How does AHK-Cu work?

The published work centres on dermal papilla cells (DPCs) — the specialised fibroblasts that drive hair follicle morphogenesis and growth. In laboratory studies, AHK-Cu stimulated DPC proliferation and shifted cell-survival signalling toward an anti-apoptotic profile.[1], [2]

Aspect	What research reports	Research relevance
Dermal papilla cells	AHK-Cu stimulated proliferation of cultured human DPCs at nanomolar concentrations.	DPCs drive follicle growth; the rationale for hair research.
Anti-apoptotic signalling	Elevated Bcl-2/Bax ratio and reduced cleaved caspase-3/PARP at 10⁻⁹ M.	A proposed survival mechanism; the apoptosis reduction itself was not statistically significant.
Copper delivery	Like GHK-Cu, AHK-Cu binds copper(II) with high affinity.	Copper is a cofactor in tissue-remodelling enzymes; the class-level hypothesis.

These are cell-culture and ex vivo findings. A molecule that keeps dermal papilla cells dividing in a dish has not been shown to regrow hair on a human scalp — the translation gap between follicle assays and clinical effect is large and, for AHK-Cu, entirely unbridged by trials.

03 / Published evidence

Peer-reviewed findings

The key study is Pyo et al. 2007 in Archives of Pharmacal Research (Seoul National University). AHK-Cu at nanomolar concentrations (10⁻¹²–10⁻⁹ M) stimulated elongation of human hair follicles ex vivo and proliferation of cultured dermal papilla cells.[1]

The same study reported a mechanistic signal: at 10⁻⁹ M, AHK-Cu elevated the Bcl-2/Bax ratio and reduced cleaved caspase-3 and PARP — markers consistent with reduced apoptosis. Notably, the measured reduction in apoptotic cell numbers itself did not reach statistical significance, which the authors stated plainly.[1]

A 2012 study in Annals of Dermatology extended this line of work, reporting further effects of AHK-Cu on dermal papilla cell growth and hair follicle models. Together these two papers constitute essentially the entire direct evidence base for AHK-Cu and hair.[2]

Broader claims about copper tripeptides come from review literature on the related GHK-Cu molecule. Those reviews describe regenerative and gene-expression findings for GHK-Cu specifically; they are context for the class, not direct evidence for AHK-Cu, and the two molecules should not be treated as interchangeable.[3]

04 / Evidence landscape

How the evidence is structured

AHK-Cu has no registered clinical trial programme of any phase. The table below maps the full published evidence base.

Category	Example	Scale	What it can show
Ex vivo follicle study	Pyo et al., 2007	Human hair follicles in culture	Follicle elongation in a laboratory assay; nothing about scalp outcomes
Cell studies	Choi et al., 2012	Cultured dermal papilla cells	Proliferation and survival signals in vitro
Human clinical trials	None exist	—	No human efficacy or safety data of any kind

This mapping reflects the published records reviewed for this August 2026 update. The complete absence of human trials is itself the headline finding: any claim of proven hair benefit in people goes beyond the evidence.[1], [2]

Afiya Labs lists an AHK-Cu reference material for laboratory research. The catalogue entry is not a medicine listing and is not presented as suitable for human use.

See the AHK-Cu catalogue entry

Shop AHK-Cu pen

05 / Safety evidence

What safety evidence exists?

There are no human safety studies of AHK-Cu in any form — topical or injectable. The published work is limited to cell cultures and ex vivo follicle assays, which cannot establish a safety profile in people.[1], [2]

The U.S. FDA has identified potential significant safety risks for copper peptides for injectable routes of administration in Category 2 of its interim compounding policy. Category placement is a regulatory risk signal, not a full safety assessment, and it concerns compounded products.[4]

Anyone reading claims about AHK-Cu use should weigh them against the total absence of controlled human data — for efficacy and for safety alike.

06 / Regulators

Status in the US, Europe, and UAE

United States

AHK-Cu is not an FDA-approved drug. Under the FDA's interim compounding policy, copper peptides for injectable routes of administration appear in Category 2 — bulk substances that may present significant safety risks in compounding. This category concerns pharmacy compounding and is not a marketing authorisation.[4]

European Union

AHK-Cu is not authorised as a medicine in the EU and has no pharmaceutical development programme in any jurisdiction.

United Arab Emirates

The Emirates Drug Establishment maintains the UAE's public registered medical product directory. We did not rely on a directory search to infer approval, non-approval, legality, availability, or permission for use of any specific product; those questions require confirmation from the EDE. Approved medicines in the UAE are dispensed through licensed channels.[5]

07 / Quick answers

Frequently asked questions

Is AHK-Cu an approved medicine?

No. AHK-Cu is not approved as a drug in the US, authorised as a medicine in the EU, or approved anywhere else. No clinical development programme exists.

Is AHK-Cu the same as GHK-Cu?

No. Both are copper-binding tripeptides, but AHK (alanyl-histidyl-lysine) differs from GHK (glycyl-histidyl-lysine) by one amino acid. Their evidence bases are separate: GHK-Cu has decades of skin research; AHK-Cu has a small hair-biology literature. Findings for one cannot be assumed for the other.

What does the research actually show?

Two peer-reviewed studies show AHK-Cu stimulates human hair follicle elongation ex vivo and dermal papilla cell proliferation in vitro at nanomolar concentrations. There are no human trials — nothing is proven about hair growth in people.

Why is AHK-Cu discussed for hair loss?

Because dermal papilla cells drive follicle growth, and the laboratory studies showed AHK-Cu affects those cells. That is a hypothesis-generating rationale, not evidence of clinical effect.

Is AHK-Cu natural?

AHK is a synthetic analogue of the naturally occurring GHK peptide. Research materials are synthetically produced.

What does the UAE directory show?

It is a public register of medical products. This guide does not turn a directory search result — or the absence of one — into a claim about approval, legality, or permitted use. The EDE is the appropriate authority for a current determination.

08 / Sources